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The ENGINE study evaluated noninvasive skin ﬂuorescence spectroscopy (SFS) for detection of abnormal
glucose tolerance (AGT). The AGT detection performance of SFS was compared to fasting plasma glucose
(FPG) and hemoglobin A1C (A1C). The study was a head-to-head comparison of SFS to FPG and A1C in an
at-risk population of 507 subjects, with no prior diagnosis of diabetes, each of whom received a
75 g, two-hour oral glucose tolerance test (OGTT). Subjects were measured by SFS on multiple days in
fasting and non-fasting states. SFS data were acquired and analyzed with the SCOUT DS device
(VeraLight, Albuquerque, NM, USA). Disease truth was AGT, deﬁned as OGTT  7.8 mmol/L. Sensitivity,
false positive rate (FPR), ROC area, and equal error rate (EER) for detection of AGT were computed. The
reproducibility of SFS and FPG was assessed. The AGT sensitivity of SFS at the device’s recommended
screening threshold of 50 was 75.2%, higher than that of FPG (thresholds of 5.6 mmol/L or 6.1 mmol/L)
and A1C (thresholds of 5.7% or 6.0%). The SFS FPR was 42.1%, comparable to an A1C threshold of
5.7% (FPR ¼ 43.5%). The EERs of SFS, FPG and A1C were similar, as were the partial ROC areas for FPRs of
20e50%. The reproducibility of SFS was 7.7% versus 8.1% for FPG. SFS had similar AGT detection per-
formance to FPG and A1C and is a viable alternative to screening individuals for AGT.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Diabetes mellitus is a growing, global health concern. The In-
ternational Diabetes Federation estimates that in 2011, 366 million
people ages 20e79 around the globe had diabetes. It is estimated
that 50% of diseased individuals are undiagnosed, with type 2
diabetes representing 90e95% of cases [1]. Another 280 million
people had impaired glucose tolerance (IGT), a signiﬁcant risk factor
for developing type 2 diabetes within 10 years [1]. By the year 2030
the prevalence of diabetes and IGT are projected to grow to 552 and
398 million people ages 20e79, respectively [2]. Persons with
diabetes are at increased risk for nephropathy, retinopathy, auto-
nomic neuropathy, peripheral neuropathies that may lead to lowerBY-NC-SA license (http://
uquerque, NM 87111, USA.
ohn.maynard@veralight.com
Published by Elsevier Inc. All rightlimb amputation, cardiovascular disease and stroke. Diabetes and
its attendant complications place a signiﬁcant burden on the health
care systems of the world, with an aggregate cost estimated at $465
billion (USD) in 2011, representing 11% of health expenditures in
adults 20e79 years of age [1]. Caring for people with diabetes may
become economically unsustainable given the projected growth of
the disease.
Early identiﬁcation and intervention have been identiﬁed as
critical components of programs seeking to prevent or delay the
onset of type 2 diabetes. The Diabetes Prevention Program (DPP)
and Finnish Diabetes Prevention Study (DPS) both demonstrated
that a 4e7% decrease in body weight coupled with 150 minutes a
week of moderate exercise could reduce the conversion from IGT to
type 2 diabetes by 58% over approximately 3 years [3,4] and by 34%
over 10 years, according to the DPP Observational Study (DPPOS)
[5]. Furthermore, DPP/DPPOS showed that pharmacological therapy
with metformin reduced conversion to type 2 diabetes by 31% over
3 years and 18% over 10 years [3,5].
Screening at-risk individuals is a critical component of pri-
mary diabetes prevention. Traditional blood-based measure-
ments of glycemia are commonly used to screen for type 2s reserved.
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centage of the at-risk population that is tested [6]. Requirements
for overnight fasting and the lag time of laboratory processing of
the blood samples represent barriers to implementing effective
diabetes screening programs [7]. The American Diabetes Associ-
ation (ADA) has recently recommended lab-based A1C for dia-
betes screening and diagnosis to eliminate fasting requirements
and reduce potential pre-analytical errors such as fasting
compliance, acute illness and in vitro glycolysis [8]. However,
laboratory-based A1C still requires drawing venous blood and
waiting for results to be reported to the physician. In contrast,
various researchers have found that risk stratiﬁcation using a
noninvasive screening measure increases participation in conﬁr-
matory blood-based testing [9,10], and that such screening ap-
proaches are most cost-effective with respect to the cost per
identiﬁed case of disease [11].
Recently, noninvasive diabetes screening based on skin ﬂuo-
rescence spectroscopy (SFS) has been proposed [12e16]. The
SCOUT DS device (VeraLight, USA) uses ﬂuorescence spectroscopy
to noninvasively measure biomarkers of diabetes in the skin,
including ﬂuorescent advanced glycation endproducts (AGEs) like
pentosidine and cross-lines as well as indicators for cell meta-
bolism and oxidative stress such as reduced nicotinamide adenine
dinucleotide (NADH) and ﬂavin adenine dinucleotide (FAD)
[17,18]. As shown in Figure 1, the tabletop device illuminates the
left volar forearm skin with low-intensity light at multiple near-
ultraviolet and visible wavelengths using light emitting diodes
(LED). A specially designed ﬁber-optic probe couples the excita-
tion light to the subject’s forearm and relays the resulting skin
ﬂuorescence and reﬂectance to a spectrograph and camera. The
SCOUT device measures the reﬂectance of each excitation LED and
automatically adjusts the LED brightness and camera exposure
time to compensate for subject speciﬁc variation in melanin
content, hemoglobin and light scattering, facilitating measure-
ment of all but the darkest skin tones. The optical signals are then
processed to produce a score that is related to the presence of
prediabetes or diabetes. The score is reported on a scale of 0e100,
with higher values indicating higher disease probability. Subjects
with a score 50 are typically considered to have screened posi-
tively and are referred for a follow-up blood test to make a diag-
nosis of prediabetes or type 2 diabetes.Methods
Objectives
The ENGINE (Evaluation of a Noninvasive Diabetes Screening
Device in Subjects at Risk for Diabetes) trial was a prospective,Figure 1. Pictures of SCOUT DS devicemulti-center validation of SFS detection of abnormal glucose
tolerance (AGT) in the subjects at-risk for but without
an established diagnosis of type 2 diabetes (clinialtrials.gov,
NCT01080157). FPG and A1C were used as comparative screening
methods. Disease truth was abnormal glucose tolerance, deﬁned
as a post-challenge plasma glucose of at least 7.8 mmol/L after a 75
gram, two-hour oral glucose tolerance test (OGTT). A secondary
study objective was to conﬁrm that SFS had a within-patient, in-
ter-day coefﬁcient of variation (CV) less than 10%. The results re-
ported here are fully prospective: all aspects of data processing,
quality assurance metrics, metric thresholds, and the prediction
algorithm were derived from a previous calibration data set and
ﬁxed prior to data unblinding. Therefore, these results constitute
the most rigorous test to date of the SFS system under realistic
operating conditions.Study design
Subjects at risk for type 2 diabetes were recruited using
clinical databases and advertising from 12 research sites
distributed across the United States. The study protocol was
approved by the Schulman Associates institutional review board
and encompassed all sites. Subjects were scheduled for three
visits to the center with a minimum of 1 day and a maximum of
two weeks separating each visit. Each site was supplied with a
single SCOUT DS instrument for measurement of skin ﬂuores-
cence and reﬂectance. Site staff were trained to explain to study
participants how to seat themselves at the device and to place
their arms on the optical sensor. The SFS devices perform auto-
mated quality control measurements as needed when subject
measurements are not being performed.
Inclusion criteriawere (i) age greater than or equal to 45 years or
(ii) age 18e44 years with a BMI >25 kg/m2 and one or more
additional ADA-deﬁned risk factors for type 2 diabetes, including
physical inactivity, ﬁrst-degree relative with diabetes, high risk
race/ethnicity, women who delivered a baby weighing >9 lbs or
diagnosed with gestational diabetes, hypertension, dyslipidemia,
womenwith PCOS, prediabetes, other clinical conditions associated
with insulin resistance or history of CVD [19]. Exclusion criteria
were participation in previous studies of the SCOUT DS device,
receiving chemotherapy in last 12 months, receiving dialysis or
compromised renal function, receiving investigational treatments
within the past two weeks, a prior diagnosis of diabetes, scars or
tattoos on the left volar forearm, or a known skin photosensitivity
condition.
On Visit 1, subjects reported to the study site in the morning
after an overnight fast of at least eight hours. Informed consent was
obtained for all subjects. Each subject completed a short healthwith and without subject forearm.
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circumference (at the midpoint between the top of the iliac crest
and inferior margin of the last rib) and blood pressure. The subject
placed his/her forearm on the SFS device and the spectral datawere
analyzed by the system to produce a SFS score for that subject (SFS
(Visit 1)). Venipuncture was performed to collect FPG (FPG (Visit 1))
and A1C (A1C (Visit 1)) specimens. The subject then consumed a
75 gm oral glucose load (glucola, 10 ﬂ oz) within 5 minutes. Two
hours  10 minutes after consumption, a venipuncture was per-
formed to collect the two hour post-challenge plasma glucose
specimen.
On Visit 2, subjects reported any time of day in a non-fasting
state to test SFS in its intended-use environment and assess the
inter-day coefﬁcient of variation (CV).
On Visit 3, subjects reported to the study site in the morning
after an overnight fast of at least 8 hours. A venipuncture was
performed for a second FPG (FPG (Visit 3)) in order to assess the
inter-day CV of FPG.Analytical methods
Plasma glucose and A1C assays were performed at local refer-
ence laboratories accredited by the College of American Pathology
(CAP) and certiﬁed in compliance with the Clinical Laboratory Im-
provements Amendments (CLIA). Each laboratory participated in
CAP proﬁciency testing and provided the results of the proﬁciency
testing for the laboratory tests being performed for the study. All
assays had to be judged as acceptable by CAP.
All blood assays were acquired by venipuncture. A1C was
collected in EDTA vacutainer tubes, mixed immediately by
repeated gentle inversion, and then refrigerated. The A1C assay
was traceable to the National Glycohemoglobin Standardization
Program (NGSP).
Plasma glucose blood samples were drawn in lithium heparin
plasma-separator vacutainer tubes, mixed by gentle inversion, and
immediately centrifuged at 2000g for 15e20 minutes. Aliquots of
the plasma specimens were placed in transfer tubes and refriger-
ated. Glucose assays utilized either the glucose oxidase or hexoki-
nase method.Figure 2. Trial ﬂow summary for the ENGINE study.Calculation
Point estimates and 95% conﬁdence intervals on the sensitivity
and false positive rate (FPR) for the detection of AGT were calcu-
lated for FPG, A1C, and SFS. Receiver operating characteristic (ROC)
curves were generated for each test, and the equal error rate (EER,
i.e., the point on the ROC where sensitivity and speciﬁcity are
equal) was computed. The area under the ROC curve (AUC) and
partial area (pAUC) for FPRs in the range of 0.2e0.5 (typical of FPG)
were also computed for each test. The FPR range for the pAUC
calculations was selected to match the typical behavior of the FPG
test; refer to the Discussion section for additional details. Partial
ROC areas were computed per Dodd and Pepe [20]. Conﬁdence
intervals on the AUC and pAUC were determined as described by
Qin et al. [21]. The sensitivities of FPG, A1C and SFS for detection of
frank diabetes (DM, deﬁned as OGTT  11.1 mmol/L) and impaired
glucose tolerance (IGT, deﬁned as 7.8 mmol/LOGTT< 11.1 mmol/
L) were also computed.
SFS and FPG measurements were recorded for each subject
at each of two visits. By collecting measurements on separate
days, the inter-day reproducibility of SFS and FPG could be
assessed. Reproducibility was assessed via the intra-individual
coefﬁcient of variation from the Hoorn study (Hoorn CV) [22],
given byHoorn CV ¼
SDdif
. ﬃﬃﬃ
2
p
median

Wj
 100;
where SDdif is standard deviation of the difference between each
subject’s ﬁrst and second measurements, and Mmean is the median
of the mean of each subject’s ﬁrst and second measurements.
Statistical analyses were performed with MATLAB 7.5 (R2007b).Results
Data description
Refer to Figure 2 for a trial ﬂow summary. A total of 537 subjects
enrolled in the ENGINE trial. Of the enrolled subjects, 15 subjects
were screen failures due to inability to collect an OGTT blood
specimen, inability to complete the 75 g glucose challenge, or lab-
oratory errors. An additional 4 subjects received two-hour OGTT
blood draws that were outside the allowable 2 hours  10 minutes
window, leaving a total of 518 subjects with complete OGTT refer-
ence data. Two subjects were not measurable on the SFS device due
to extremely low signal (<1% of expected reﬂectance at 375 nm
excitation wavelength). In addition, 9 subjects were lost to follow-
up and did not complete the 3-visit sequence of the ENGINE trial,
leaving a total of 507 subjects who completed the entire protocol.
Valid ﬁrst attempt SFS (Visit 2) values were obtained from 408 of
the 507 (80%) subjects who completed the ENGINE study and from
482 of 507 subjects (95%) if a single retry was allowed in the case
that the ﬁrst attempt failed. Invalid SFS measurements most
commonly resulted from (i) failure to collect a complete set of SFS
data (n ¼ 36, due to failure of one or more automated data quality
Table 2
Demographic characteristics of the ENGINE analysis set versus study completers
with a valid OGTT result who were not in the primary analysis set.
Primary
analysis set
n ¼ 408 (80%)
Completers,
not in primary
analysis set
n ¼ 99 (20%)
p value
Gender 0.202a
Male 173 (42%) 49 (49%)
Female 235 (58%) 50 (51%)
Ethnicity 0.576a
White 254 (62%) 55 (56%)
Latino 76 (19%) 20 (20%)
Af.Amer. 65 (16%) 19 (19%)
Other 13 (3%) 5 (5%)
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lights in the ﬂuorescence data) or (ii) identiﬁcation of the acquired
spectral data as an outlier (n ¼ 63, most commonly due to suc-
cessive forearm measurements resulting in dissimilar spectra due
to inconsistent contact with the optical sensor). All outlier metrics
and thresholds were pre-speciﬁed and were developed exclusively
from a separate and previously collected algorithm training data
set. The study protocol did not provide time for subjects who failed
to obtain a valid SFS score to make an additional measurement
attempt during Visit 2. The primary analysis looked at the 408
subjects with valid ﬁrst attempt SFS measurements and a second-
ary analysis looked at the 482 subjects who had valid SFS mea-
surements on the ﬁrst or second attempts.Parent with diabetes 137 (34%) 37 (37%) 0.476a
Sibling with diabetes 59 (14%) 15 (15%) 0.861a
Hypertensive 96 (24%) 26 (26%) 0.568a
Age (years) 51.6  13.6 53.0  12.9 0.494b
BMI (kg/m2) 31.0  6.9 31.4  7.2 0.661b
Waist, male (in) 40.8  5.5 41.9  6.8 0.344b
Waist, female (in) 38.0  6.7 39.5  6.0 0.107b
2-hour glucose
on OGTT (mg/dL)
7.1  3.2 7.1  2.6 0.675b
FPG (mg/dL) 5.5  1.2 5.6  0.7 0.011b
A1C (%) 5.8  0.7 5.8  0.5 0.041b
AGT 109 (27%) 34 (34%) 0.130a
AGT ¼ abnormal glucose tolerance.
a Pearson’s c2 test.
b Wilcoxon rank sum test.Cohort description
The demographic characteristics of the 408 subjects in the pri-
mary analysis set are summarized in Table 1. The AGT prevalence
was 26.7%. The AGTand normal glucose tolerance (NGT) groups had
similar distributions of gender and family history of diabetes.
Subject age, BMI, hypertension, and waist circumference were all
signiﬁcantly higher in subjects with AGT versus NGT. The ethnicities
of the AGT and NGT groups were different (p ¼ 0.002). The AGT
group had 65% Caucasian, 22% Latino and 6% African American
subjects, versus 61% Caucasian, 17% Latino, and 19% African Amer-
ican in the NGT group.
The demographic characteristics of the 408-member primary
analysis set were also compared to those subjects who completed
the ENGINE protocol but failed to obtain a valid SFS (Visit 2) score
on the ﬁrst attempt for the reasons described above (Table 2). None
of the above-mentioned demographic properties were signiﬁcantly
different between the two groups. The standard deviations of the
FPG and A1C values for subjects in the primary analysis set were
slightly larger than those for subjects without a valid ﬁrst attempt
SFS (Visit2) score (1.2 vs 0.7mmol/L for FPG and 0.7 vs 0.5% for A1C).
However, the mean FPG and A1C values of subjects in the primaryTable 1
Demographic characteristics of the ENGINE cohort expressed as either number (%) or
mean  standard deviation.
Normal glucose
tolerance (NGT)
n ¼ 299
Abnormal glucose
tolerance (AGT)
n ¼ 109
p value
Gender 0.96a
Male 127 (42%) 46 (42%)
Female 172 (58%) 63 (58%)
Ethnicity
White 183 (61%) 71 (65%)
Latino 52 (17%) 24 (22%)
Af.Amer. 58 (19%) 7 (6%)
Other 6 (2%) 7 (6%) 0.002a
Parent with diabetes 96 (32%) 41 (38%) 0.30a
Sibling with diabetes 40 (13%) 19 (17%) 0.30a
Hypertensive 59 (20%) 37 (34%) 0.003a
Age (years) 50.2  13.7 55.5  12.4 <0.001b
BMI (kg/m2) 30.0  6.5 33.8  7.1 <0.001b
Waist, male (in) 40.1  5.1 42.8  6.2 0.01b
Waist, female (in) 36.8  6.3 41.3  6.8 <0.001b
2-hour glucose
on OGTT (mmol/L)
5.8  1.1 10.8  4.0 N/Ac
FPG (mg/dL) 5.2  0.5 6.1  2.0 <0.001b
A1C (%) 5.6  0.3 6.2  1.1 <0.001b
SFS Score 49.1  9.3 55.9  9.7 <0.001b
a Pearson’s c2 test.
b Wilcoxon rank sum test.
c AGT and NGT groups were stratiﬁed on the basis of an OGTT threshold of
7.8 mmol/L.analysis set were very similar to those of subjects without a valid
SFS (Visit 2) score (5.5 vs 5.6 mmol/L for FPG, 5.8% vs 5.8% for A1C).
In addition, neither the AGT prevalence nor the distributions of
OGTT values were signiﬁcantly different between the two groups.
Thus, there is no evidence of selection bias in the individuals who
were able to obtain a valid SFS (Visit 2) score on the ﬁrst attempt
versus those who were not.Figure 3. ENGINE study ROC curves for detection of abnormal glucose tolerance (AGT)
for SFS DS (Visit 2), FPG (Visit 1) and A1C (Visit 1). The white region denotes
0.2  FPR  0.5, which is the range used to compute the partial ROC areas in Table 2.
Table 3
Summary of screening test performance metrics as compared with OGTT.
Test AGT AUC [95% CI] AGT equal
error rate (%)
AGT pAUC
0.2  FPR  0.5 [95% CI]
Threshold AGT false
positive rate (%) [95% CI]
AGT sensitivity
(%) [95% CI]
SFS (Visit 2, No Retry) 0.711 [0.655e0.767] 33.0 0.203 [0.174e0.231] 50 42.1 [36.7e47.8] 75.2 [66.4e82.4]
SFS (Up to One Retry) 0.701 [0.650e0.753] 33.4 0.199 [0.172e0.225] 50 42.5 [37.4e47.7] 75.0 [67.0e81.6]
FPG (Visit 1) 0.735 [0.679e0.792] 33.0 0.204 [0.176e0.233] 5.6 mmol/L
6.1 mmol/L
23.7 [19.3e28.9]
7.4 [4.9-10.9]
56.0 [46.6e64.9]
37.6 [29.1e47.0]
A1C (Visit 1) 0.740 [0.688e0.791] 31.8 0.204 [0.166e0.242] 5.7%
6.0%
43.5 [38.0e49.1]
15.1 [11.4e19.5]
72.5 [63.4e80.0]
46.8 [37.7e56.1]
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Because skin ﬂuorescence spectroscopy is not inﬂuenced by
fasting status and is intended to be performed in a non-fasting
state, the primary analysis compared SFS detection of AGT from
the non-fasting visit (Visit 2) to that of FPG and A1C. The AGT ROC
curves for SFS (Visit 2) (blue/solid line), FPG (Visit 1) (red/dashed
line) and A1C (Visit 1) (green/dash-dotted line) are shown in
Figure 3. Points indicate performance of the tests at their respective
screening thresholds of 50 AU (SFS, blue circle), 5.6 mmol/L (FPG,
solid red square), 6.1 mmol/L (FPG, open red square), 5.7% (A1C,
solid green triangle), 6.0% (A1C, open green triangle).The ROC
curves for SFS, FPG, and A1C are very similar for FPR > 0.2, with
nearly identical pAUCs for 0.2  FPR  0.5.
Table 3 is a summary of the AUC, pAUC, equal error rate,
sensitivity, and FPR for SFS and the FPG and A1C tests using the
screening thresholds depicted in Figure 3 as well as SFS if a single
measurement retry was allowed. The AGT sensitivity of SFS at its
decision threshold of 50 was higher than that of FPG at the 5.6 and
6.1 mmol/L thresholds and of A1C at the 5.7% and 6.0% thresholds.
The AGT FPR of SFS was higher than that of FPG but comparable to
A1C at a 5.7% threshold. The SFS threshold favors test sensitivity at
the expense of a moderate FPR, while the A1C and FPG thresholds
of 6.0% and 6.1 mmol/L, respectively, favor lower FPR at the
expense of sensitivity. SFS and FPG had equal error rates of 33%;
the equal error rate of A1C was 32%. The SFS pAUC for detection of
AGT was 0.203 (0.199 with one retry), which is comparable to and
not signiﬁcantly different from the FPG and A1C pAUCs, both of
which were 0.204. The sensitivity of SFS for undiagnosed diabetes
(OGTT  11.1 mmol/L) was 79.3%, equal to that of FPG at a
threshold of 5.6 mmol/L (79.3%) and comparable to that of A1C at
a threshold of 5.7% (sensitivity ¼ 86.2%). The sensitivity of SFS
(73.8%) for detection of IGT was higher than that of FPG (47.5%,
27.5%) or A1C (67.5%, 36.3%) at either of the thresholds evaluated
for these tests.
The inter-day Hoorn coefﬁcients of variation were 7.7% for SFS
(SFS (Visit 1) vs SFS (Visit 2)) and 8.1% for FPG (FPG (Visit 1) vs FPG
(Visit 3)).
Although the primary analysis considered SFS performance from
Visit 2 (non-fasting), additional analyses found that SFS ROC met-
rics (AUC¼ 0.701, pAUC¼ 0.206) and sensitivity (70.5%) at SFS¼ 50
from fasting Visit 1 measurements were not signiﬁcantly different
from those of Visit 2. The fasting Visit 1 FPR of SFS was statistically
signiﬁcantly lower than the non-fasting Visit 2 FPR (33.3% vs 42.1%).
Discussion
The ENGINE study results indicate that SFS is effective for
screening individuals at risk for pre-diabetes and type 2 diabetes.
Speciﬁcally, when screening for abnormal glucose tolerance, the
ROC curve of SFS was comparable to that of FPG and A1C for
0.2  FPR  0.5. In a review of FPG AGT screening performance in
large cohorts of at-risk, previously-undiagnosed subjects, the FPR ofthe FPG test at the ADA-recommended impaired fasting glucose
cutpoint of 5.6 mmol/L was found be constrained to this range
([23e26], Supplementary Table 1). The inter-day Hoorn coefﬁcient
of variation of SCOUT DS (7.7%) was comparable to that of the FPG
test (8.1%).
Detection of undiagnosed diabetes is also a critical aspect of
primary diabetes screening: the United Kingdom Prospective
Diabetes Study (UKPDS) established the importance of glycemic
control for reducing the risk of developing the diabetes-related
complications [27,28]. In addition, tools that facilitate effective
AGT screening are important because impaired glucose tolerance
is recognized as an early risk indicator for development of type 2
diabetes as well as cardiovascular disease. For example, Tominga
et al found that the hazard ratio for death from cardiovascular
disease was signiﬁcantly elevated for individuals with IGT versus
NGT (ratio ¼ 2.2), but not for individuals with impaired versus
normal fasting glucose (ratio ¼ 1.1) [29]. Other studies have also
established a strong association between cardiovascular compli-
cations and compromised glucose tolerance [30,31], and primary
diabetes prevention studies such as the DPP/DPPOS and DPS
have traditionally focused on altered glucose tolerance as the
most reliable early indicator of glycemic dysfunction in type
2 diabetes [3e5].
It is therefore desirable that a primary diabetes screening test be
as sensitive as possible in identifying individuals with abnormal
glucose tolerance. The balance between a test’s sensitivity and false
positive rate is described by the ROC curve. As seen in Figure 3/
Table 3, the SFS threshold of 50 AU exhibited the highest AGT
sensitivity (75.2%) of all screening tests involved in the ENGINE trial.
The FPR of SFS was 42.1%, which was slightly lower than that of the
A1C test (43.5%) at the ADA-recommended screening threshold of
5.7% [8]. The FPR of the FPG test was lower (23.7% at the ADA-
recommended threshold of 5.6 mmol/L), but at the cost of
decreased AGT sensitivity (56.0%).
While a low FPR is highly desirable for a diagnostic test, where
false positives lead to costly and unnecessary treatment, selecting a
moderate FPR in order to maximize AGT sensitivity in primary
screening is well justiﬁed if ruling out disease in the false positive
cases is not excessively inconvenient and/or costly relative to the
beneﬁts of early detection and intervention. In a recent modeling
study, Chattergee et al found that widespread opportunistic
screening for type 2 diabetes was economically superior to the case
of no or limited screening, after accounting for the costs of
screening and therapeutic intervention, even for moderate false
positive rates such as those reported here [32]. Similarly, a detailed
model by Herman et al found that widespread opportunistic
screening and implementation of the DPP interventions were cost-
effective or marginally cost-saving, even if metformin therapy was
extended to individuals as old as 65 years of age [33].
There is ongoing debate in the public health community as to
the economic beneﬁt of widespread diabetes screening. For
example, citing a study that showed no effect of diabetes screening
onmortality, the Canadian Task Force on Prevention Periodic Health
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or DM is not indicated [34]. Nevertheless, in an effort to reduce the
economic burden of caring for those with the disease and to
improve workforce productivity, national diabetes screening efforts
are being implemented by governments throughout the world.
Examples include the National Diabetes Prevention Program
(http://www.cdc.gov/diabetes/prevention/about.htm) in the United
States and the National Programme for Prevention and Control of
Diabetes, Cardio-Vascular Diseases and Stroke in India [35]. In
addition, several provisions in the United States Patient Protection
and Affordable Care Act (2010) directly address gaps in diabetes
screening, prevention, and therapy.
While the need for effective primary screening methods for
those at risk is generally accepted, multiple obstacles limit the
effectiveness of existing blood-based screening modalities. Patient
convenience and compliance are barriers to the effectiveness of FPG
and OGTT, which require overnight fasting [7,9]. As shown above,
FPG suffers from poor sensitivity at its typical screening thresholds.
The need to properly handle and dispose of biohazardous waste
generated by blood-based methods may be an additional obstacle
in certain instances such as employee wellness clinics or commu-
nity health fairs.
A limitation of the study is the fact that was cross-sectional and
only shows the association of SFS with current impaired glucose
tolerance or undiagnosed type 2 diabetes. A longitudinal study
would be more powerful in elucidating an SFS threshold that pre-
dicts the development of type 2 diabetes.
Strengths of the study include that all members of the study
cohort were at risk for type 2 diabetes by ADA guidelines and
therefore members of the intended-use population. In addition,
head-to-head SFS, FPG, A1C, and OGTT data were acquired. The
cohort also had a representative mixture of patient age, gender,
ethnicity, and BMI. The clinically-realistic, multi-center, multi-
device nature of the ENGINE trial represents an additional strength.
Conclusion
The elimination of overnight fasting, the absence of blood, and
the rapid, real-time communication of screening results are aspects
of noninvasive skin ﬂuorescence spectroscopy that facilitate
opportunistic screening of individuals at risk for type 2 diabetes
while delivering performance that is comparable to FPG and A1C for
detection of abnormal glucose tolerance.
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Supplementary Table 1
Performance of FPG when screening for abnormal glucose tolerance at a test threshold of 5.6 mmol/L. Disease truth is deﬁned as a two-hour OGTT result of at least 7.8 mmol/L.
Data set Number of subjects Disease prevalence FPG FPR FPG sensitivity
NHANES III, Phase 1 (1988-91)a [23] 1460 28.0% 36.7% 66.1%
NHANES III, Phase 2 (1991-94)a [23] 1566 28.9% 26.9% 62.5%
NHANES 05-06a [24] 1293 26.6% 34.9% 74.7%
NHANES 07-08a [25] 1512 29.6% 49.0% 75.9%
Robles-Osorio et al. [26] 1239 36.7% 18.9% 54.9%
a At-risk population (per ADA guidelines) only, weighted per NHANES guidelines to reﬂect overall US demographics for age 18.
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